An investigational intranasal drug, USL261, is being studied in outpatients with partial or generalized epilepsy as a "rescue therapy" for the treatment of seizure clusters.
Researchers invite those patients aged 14-65 who are diagnosed with partial or generalized epilepsy to see if they may be eligible to participate in the ARTEMIS1 Study. The purpose of this clinical research study is to determine the safety and effectiveness of an investigational drug compared with intranasal placebo for the outpatient treatment of seizure clusters.
The investigational drug is given as a nose spray that is being studied as an at-home rescue treatment of seizure clusters for patients with partial or generalized epilepsy.
Each individual will be evaluated to determine his or her eligibility to participate in the study. You can participate even if the study doctor is not part of your health insurance network, or if you don’t have health insurance. Those enrolled will receive study drug, study-related medical examinations, and laboratory tests at no charge. Reimbursement for time and travel may also be available.